Novel treatment for refractory neuroblastoma by using poliovirus; phase I clinical trial

Novel treatment for refractory neuroblastoma by using poliovirus; phase I clinical trial - Novel treatment for refractory neuroblastoma by using poliovirus; phase I clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029816

Enrollment

Registered

2017-11-03

Start date

2009-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory neuroblastoma

Interventions

intratumoral administration of poliovirus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: refractory neuroblastoma

Exclusion criteria

Exclusion criteria: patients who have paralysis

Design outcomes

Primary

Measure	Time frame
safety (paralysis) and efficacy (anti-tumor effect) at 6 months after administration	—

Countries

Japan

Contacts

Public ContactHidemi Toyoda

Mie University Hospital Pediatrics

htoyoda@clin.medic.mie-u.ac.jp059-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026